{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:03Z","timestamp":1787027883213,"version":"build-2736575974"},"reference-count":44,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>The aim of our study was to evaluate the incidence of KRAS\/NRAS and BRAF mutations, analyze molecular patterns, and investigate associations with clinical parameters of these mutations in CRC KRAS\/NRAS and BRAF mutations analyzed by next-generation sequencing. The detection rates of these mutations and patients\u2019 demographics were recorded and the relationship between them was evaluated using the chi-square test. KRAS mutation was detected in 332 of 694 patients, while the mutation rates in KRAS exons 2\/3 and 4 were 39.6%\/3.2% and 5%, respectively. The most common mutation pattern was KRAS G12D. Five atypical variants were detected: V14I in KRAS exon 2, A18D, Q22K and T50I in exon 3, and T148P in exon 4. NRAS mutation was detected in 29 (4.5%) patients. One atypical variant L80W was detected in NRAS exon 3. BRAF mutation was seen in 37 (5.3%) patients, with BRAFV600E (83.8%) being the most common mutation pattern. NRAS mutation was significantly more frequent in patients &gt; 64 years of age, BRAF mutation in women, and NRAS\/BRAF mutations in right colon tumors. Grouping BRAF mutations into BRAFV600E and BRAFnon-V600E and their analysis according to specific tumor localizations showed that all four BRAFnon-V600E mutations originated in the rectum. In our study, KRAS exon 2 and other RAS mutation rates were higher than in the literature, while the BRAF v.600E mutation rate was similar. NRAS and BRAF mutations were significantly more frequent in the right colon. BRAF mutation was more common in women and in the right colon.<\/jats:p>","DOI":"10.3390\/cimb45100491","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:58:17Z","timestamp":1695718697000},"page":"7803-7812","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Molecular Pattern and Clinical Implications of KRAS\/NRAS and BRAF Mutations in Colorectal Cancer"],"prefix":"10.3390","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-5396","authenticated-orcid":false,"given":"\u0130vo","family":"G\u00f6kmen","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne 22030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7686-7765","authenticated-orcid":false,"given":"Ebru","family":"Ta\u015ftekin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Trakya University School of Medicine, Edirne 22030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2988-4450","authenticated-orcid":false,"given":"Nazan","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sultan I. Murat Public Hospital, Edirne 22030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1562-6340","authenticated-orcid":false,"given":"Erkan","family":"\u00d6zcan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne 22030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-1093","authenticated-orcid":false,"given":"Fahri","family":"Akg\u00fcl","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne 22030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-3239","authenticated-orcid":false,"given":"Muhammed Bekir","family":"Hac\u0131o\u011flu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne 22030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-3490","authenticated-orcid":false,"given":"B\u00fclent","family":"Erdo\u011fan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne 22030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5387-8309","authenticated-orcid":false,"given":"Sernaz","family":"Topalo\u011flu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne 22030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-3868","authenticated-orcid":false,"given":"\u0130rfan","family":"\u00c7i\u00e7in","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne 22030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Cervantes","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1053\/j.gastro.2008.02.098","article-title":"Systemic treatment of colorectal cancer","volume":"134","author":"Wolpin","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_6","first-page":"Cd007047","article-title":"Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer","volume":"6","author":"Chan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000258497","article-title":"The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: The KRAS\/BRAF pathway","volume":"77","author":"Russo","year":"2009","journal-title":"Oncology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1056\/NEJMra0804588","article-title":"Molecular origins of cancer: Molecular basis of colorectal cancer","volume":"361","author":"Markowitz","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1158\/1078-0432.CCR-08-0333","article-title":"Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway","volume":"14","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis","volume":"11","author":"Claes","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2217\/bmm-2016-0358","article-title":"RAS mutation prevalence among patients with metastatic colorectal cancer: A meta-analysis of real-world data","volume":"11","author":"Kafatos","year":"2017","journal-title":"Biomark. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2015.05.017","article-title":"Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials","volume":"51","author":"Peeters","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_13","first-page":"579","article-title":"Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: Analyses of 966 cases","volume":"41","author":"Gao","year":"2012","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.2015.63.9674","article-title":"Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015","volume":"34","author":"Allegra","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/1319-3767.207712","article-title":"BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis","volume":"23","author":"Li","year":"2017","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/annonc\/mdw261","article-title":"Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: Pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group","volume":"27","author":"Modest","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.18.01798","article-title":"Mutational Analysis of Patients With Colorectal Cancer in CALGB\/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome","volume":"37","author":"Innocenti","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.clcc.2017.10.006","article-title":"Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study","volume":"17","author":"Kayhanian","year":"2018","journal-title":"Clin. Color. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bellio, H., Fumet, J.D., and Ghiringhelli, F. (2021). Targeting BRAF and RAS in Colorectal Cancer. Cancers, 13.","DOI":"10.3390\/cancers13092201"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.21037\/jgo.2016.06.12","article-title":"RAS and BRAF in metastatic colorectal cancer management","volume":"7","author":"Gong","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/jayao.2014.0006","article-title":"Colorectal Cancer Incidence Among Young Adults in California","volume":"3","author":"Singh","year":"2014","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000443644","article-title":"Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis","volume":"33","author":"Nitsche","year":"2016","journal-title":"Dig. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ejca.2015.04.007","article-title":"FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"51","author":"Bokemeyer","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Folprecht","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Lenz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.13181\/mji.v27i3.1719","article-title":"The low prevalence of colonic serrated adenocarcinoma with high KRAS mutational status at Cipto Mangunkusumo Hospital, Indonesia","volume":"27","author":"Rahadiani","year":"2018","journal-title":"Med. J. Indones."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.15537\/smj.2019.12.24699","article-title":"Colorectal cancer patients in western Saudi Arabia. Outcomes and predictors for survival over a 10-years period (2002\u20132014)","volume":"40","author":"Bakarman","year":"2019","journal-title":"Saudi Med. J."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Afolabi, H., Salleh, S.M., Zakaria, Z., Seng, C.E., Nafil, S.N.B.M., Aziz, A.A.B.A., Wada, Y., and Irekeola, A. (2022). A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population. BioMed Res. Int., 2022.","DOI":"10.1155\/2022\/5824183"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/172460080702200102","article-title":"Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer","volume":"22","author":"Symvoulakis","year":"2007","journal-title":"Int. J. Biol. Markers"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26279","DOI":"10.18632\/oncotarget.25180","article-title":"KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B\/FOx adding bevacizumab (BEV) to triplet chemotherapy","volume":"9","author":"Bruera","year":"2018","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.currproblcancer.2018.05.001","article-title":"Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients","volume":"42","author":"Hamzehzadeh","year":"2018","journal-title":"Curr. Probl. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1158\/1078-0432.CCR-21-0180","article-title":"Clinical and Functional Characterization of Atypical KRAS\/NRAS Mutations in Metastatic Colorectal Cancer","volume":"27","author":"Loree","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/cam4.2747","article-title":"Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis","volume":"9","author":"Bylsma","year":"2020","journal-title":"Cancer Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/cncr.28599","article-title":"Mutational analysis and clinical correlation of metastatic colorectal cancer","volume":"120","author":"Russo","year":"2014","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e24868","DOI":"10.1002\/jcla.24868","article-title":"KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients","volume":"37","author":"Asl","year":"2023","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Gil Ferreira, C., Aran, V., Zalcberg-Renault, I., Victorino, A.P., Salem, J.H., Bonamino, M.H., Vieira, F.M., and Zalis, M. (2014). KRAS mutations: Variable incidences in a Brazilian cohort of 8234 metastatic colorectal cancer patients. BMC Gastroenterol., 14.","DOI":"10.1186\/1471-230X-14-73"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"184","DOI":"10.14740\/gr1167","article-title":"A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer","volume":"13","author":"Bylsma","year":"2020","journal-title":"Gastroenterol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1200\/JCO.21.02541","article-title":"BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape","volume":"40","author":"Ciombor","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/45\/10\/491\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:58:07Z","timestamp":1760129887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/45\/10\/491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cimb45100491"],"URL":"https:\/\/doi.org\/10.3390\/cimb45100491","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]}}}